Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid β Peptides-Reference-Cited by-同舟云学术

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid β Peptides

Published:2006-02-01 Issue:2 Volume:52 Page:332-334
ISSN:0009-9147
Container-title:Clinical Chemistry
language:en
Short-container-title:

Author:

Lewczuk Piotr¹²,Beck Georg¹,Esselmann Hermann³,Bruckmoser Ralf¹,Zimmermann Rüdiger¹,Fiszer Magdalena¹,Bibl Mirko³,Maler Juan Manuel¹²,Kornhuber Johannes¹²,Wiltfang Jens¹²

Affiliation:

1. Department of Psychiatry, and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany

2. Center for, Clinical Neuroproteomics, Erlangen, Germany

3. Department of Psychiatry, and Psychotherapy, University of Goettingen, Goettingen, Germany

Publisher

Oxford University Press (OUP)

Subject

Biochemistry, medical,Clinical Biochemistry

Link

http://academic.oup.com/clinchem/article-pdf/52/2/332/32685248/clinchem0332.pdf

Reference11 articles.

1. Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease: original data and review of the literature. J Mol Neurosci2004;23:115-122.

2. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, Paul S, et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J Neurochem2002;81:481-496.

3. Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, et al. Elevation of β-amyloid peptide 2–42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cells. J Biol Chem2001;276:42645-42657.

4. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol2001;58:373-379.

5. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol1998;55:937-945.

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting;Molecular Neurodegeneration;2024-05-15

2. Specific Binding of Alzheimer’s Aβ Peptides to Extracellular Vesicles;International Journal of Molecular Sciences;2024-03-26

3. Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer’s disease;Expert Review of Molecular Diagnostics;2023-11-03

4. Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C;Neurological Research and Practice;2023-06-29

5. Neurodegeneration Markers in the Cerebrospinal Fluid of 100 Patients with Schizophrenia Spectrum Disorder;Schizophrenia Bulletin;2022-10-06